Dr.PRITHVI B

Dr. M. VANATHI, Dr. M. VANATHI, Dr. NOOPUR PARAKH, Dr. (Mrs.) RADHIKA TANDON

Abstract

Severe refractory dry eye disease (DED) in oGVHD responds poorly to therapy with resultant increase in ocular surface morbidity.

Prospective longitudinal non-comparative open-label clinical trial of chronic refractory oGVHD, with DED with adjunct APL therapy was done. Study parameters included severity, ocular surface evaluation [conjunctival hyperemia, FTBUT, Schirmer’s,l staining score, OSDI], tear protein & MMP-9 [baseline & 6 months] with 6-months follow-up (FU).

In 16 eyes, improvement in OSDI (p<0.01), conjunctival hyperemia (p<0.001) noted at 1M FU; Schirmer’s (p<0.01), CFS (<0.002), conjunctival score (p<0.001), FTBUT (p<0.001) at 3M FU was noted with decrease frequency of topical lubricants (p<0.001), steroids (p<0.02). Significant clinical improvement was noted in 87.5% of our study eyes of oGVHD . Adjunct biological tear replacement with topical APL drops is effective in significant reduction of steroid dependency with continued topical immunosuppressant therapy.

Full Text